Seres Therapeutics (NASDAQ:MCRB) is a biotechnology company focused on transforming the lives of patients by targeting the microbiome to treat disease and improve human health. It is at the forefront of microbiome therapeutics, advancing a novel class of biological drugs. Seres is engaged in developing a portfolio of product candidates designed to restore the natural ecology of the human microbiome for patients affected by serious diseases. Their projects include therapies for conditions such as Clostridioides difficile infection, ulcerative colitis, and others within the gastrointestinal disease area. The company's objective is to lead in microbiome therapeutics by advancing science and exploring new treatment modalities for a range of diseases linked to the dysfunction of the microbiome.